乐
乐观
乐观 · 25%CLGN
$10.06
情景价格
$3.970
+0.030 (+0.76%)收盘时
Loading chart…
- 最高
- 4.189
- 开盘
- 4.180
- 成交量加权均价
- 4.00
- 成交量
- 29.22K
- 市值
- 57.27M
- 最低
- 3.850
- 成交额
- 116.96K
- 企业价值/息税折旧摊销前利润（TTM）
- -0.06
CollPlant Biotechnologies Ltd, formerly known as Collplant Holdings Ltd, is a company dealing in aesthetic medicine and regenerative medicine based in Israel. The company provides products and technologies for broadly understood regenerative medicine, including tissue regeneration and organ production. The technology is based on plants and is based on the production of collagen type I (rhCollagen).
AI 分析 of Collplant Biotechnologies Ltd (CLGN)
持有CollPlant Biotechnologies Ltd is not a strong buy right now due to its current price of $3.97, which is significantly below its 52-week high of $22.50, indicating a potential for recovery but also high risk. The company has a forward P/E ratio of 80, suggesting that it is highly valued relative to its earnings, which are currently negative. Additionally, the RSI is at 47.809, indicating a neutral momentum, and the stock has experienced a year-to-date change of -73.18%, reflecting ongoing challenges. The main risk is its high volatility, with an implied volatility of 671.43%, which could lead to significant price swings.
估值指标
Collplant Biotechnologies Ltd（CLGN）当前预期市盈率为 80.00，5 年平均预期市盈率为 16.78。
Alphio AI 对 CLGN 的价格情景
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重（25 / 50 / 25），不构成保证。
事件时间线
资讯
8.510-09PRnewswireCollPlant Secures Private Placement to Accelerate R&D
3.510-06PRnewswireCollPlant Advances Photonic Computing Strategy
3.510-06NewsfilterCollPlant Advances Photonic Computing Strategy Through LightSolver's IP Growth
8.509-30PRnewswireCollPlant Expands into Photonic Computing with LightSolver Acquisition
- 8.509-30Newsfilter
CollPlant Acquires LightSolver to Expand Technology Portfolio
CLGN 常见问题 —— 由 Alphio AI 解答
CollPlant Biotechnologies Ltd, formerly known as Collplant Holdings Ltd, is a company dealing in aesthetic medicine and regenerative medicine based in Israel. The company provides products and technologies for broadly understood regenerative medicine, including tissue regeneration and organ production. The technology is based on plants and is based on the production of collagen type I (rhCollagen). It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC, AND SURGICAL APPLIANCES AN industry).
CollPlant Biotechnologies Ltd is not a strong buy right now due to its current price of $3.97, which is significantly below its 52-week high of $22.50, indicating a potential for recovery but also high risk. The company has a forward P/E ratio of 80, suggesting that it is highly valued relative to its earnings, which are currently negative. Additionally, the RSI is at 47.809, indicating a neutral momentum, and the stock has experienced a year-to-date change of -73.18%, reflecting ongoing challenges. The main risk is its high volatility, with an implied volatility of 671.43%, which could lead to significant price swings.
社区
更多 ↗暂无帖子
注册或登录后参与讨论相关文章
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。